ArticleAnnals of biomedical engineering2025
Dual-Contrast Agent with Nanoparticle and Molecular Components in Photon-Counting Computed Tomography: Assessing Articular Cartilage Health.
Article in Annals of biomedical engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Pediatric pseudo-tumor of the ischio-pubic ramus in virtual non-calcium photon-counting scanner: A case report.Radiology case reports · 2026Article
- Exploring cartilage development and disease models: applications of cartilage organoids.Inflammation and regeneration · 2026Review
- Article
- Advances in multimodal imaging techniques in nanomedicine: enhancing drug delivery precision.RSC advances · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
purposePhoton-counting detectors (PCDs) are cutting-edge technology that enable spectral computed tomography (CT) imaging with a single scan. Spectral imaging is particularly effective in contrast-enhanced CT (CECT) imaging, especially when multiple contrast agents are utilized, as materials are distinguishable based on their unique X-ray absorption. One application of CECT is joint imaging, where it assesses the structure and composition of articular cartilage soft tissue. This evaluates articular cartilage and reveals compositional changes associated with early-stage osteoarthritis (OA) using a photon-counting detector CT (PCD-CT) technique combined with a dual-contrast agent method.
methodsA dual-contrast agent combination was used, consisting of proteoglycan-binding cationic tantalum oxide nanoparticles, developed in our lab, and a commercial non-ionic iodinated iodixanol agent. Ex vivo equine stifle joint cartilage samples (N = 30) were immersed in the contrast agent bath for 96 hours and imaged at multiple timepoints for analysis of proteoglycan, collagen, and water contents as well as collagen orientation, histological scoring, and biomechanical parameters.
resultsBy analyzing contrast agent concentrations, the technique provided a simultaneous assessment of the solid constituents and function of cartilage. Contrast agent diffusion depended on contrast agent composition and was significantly different between healthy and early-stage OA groups within 12 hours.
conclusionThe present study shows the promising utility of the dual-contrast PCD-CT technique for articular cartilage assessment and early-stage OA detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.